However, activation and proliferation of antigen-activated intratumoral CD8+ T cells have been observed in cancer patients following treatment with pegilodecakin, a pegylated recombinant IL-10 (42, 43), and the intratumoral expression of IL-23 was proven to be effective in several tumor models (44). The gene discussed is CD8A; the disease is cancer.